Efficacy of Dose Escalation of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
المؤلف | Ebad Ur Rehman, Mohammad |
المؤلف | Tahir, Ammara |
المؤلف | Hussain, Amna |
المؤلف | Ali, Aizaz |
المؤلف | Bin Gulzar, Abu Huraira |
المؤلف | Khan, Abdul Qadeer |
المؤلف | Sajjad, Maha |
المؤلف | Shahid, Fatima |
المؤلف | Zahid, Shahroon |
المؤلف | Aslam, Ummara |
المؤلف | Yasin, Talha Bin |
المؤلف | Bilal, Aqsa |
المؤلف | Fatima, Tehreem |
المؤلف | Hameed, Muhammad Sheraz |
المؤلف | Haider, Tehseen |
المؤلف | Saeed, Sajeel |
المؤلف | Nashwan, Abdulqadir J. |
تاريخ الإتاحة | 2025-04-13T04:46:18Z |
تاريخ النشر | 2025 |
اسم المنشور | Medical Principles and Practice |
المصدر | Scopus |
المعرّف | http://dx.doi.org/10.1159/000543831 |
الرقم المعياري الدولي للكتاب | 10117571 |
الملخص | Background: Ustekinumab is an effective drug in the treatment of inflammatory bowel disease (IBD), but inadequate response or loss of response is reported in several patients. Dose escalation by intravenous reinduction or interval shortening may be a suitable option to recapture response. We undertook a systematic review and metaanalysis to assess the efficacy of dose escalation in IBD patients receiving ustekinumab. Methods: A systematic literature search was conducted on PubMed, Embase, Clinicaltrails.gov, and Cochrane from inception to June 1, 2024. We conducted a proportional meta-analysis on MetaXL. Our primary outcomes were clinical response and clinical remission. Results: Twenty-eight articles were included (n = 2,129 patients). Eighteen studies (692 patients out of 1,218) reported clinical response, with pooled prevalence of 55% (95% CI: 46-65%). Out of 1,041 patients, 524 showed clinical remission with pooled prevalence of 51% (95% CI: 42-59%). Conclusion: This systematic review and meta-analysis showcased promising results, in terms of clinical response and remission, in IBD patients receiving dose escalation of ustekinumab. |
راعي المشروع | Open access funding was provided by the Qatar National Library. The funder had no role in the design, data collection, data analysis, and reporting of this study. |
اللغة | en |
الناشر | S. Karger AG |
الموضوع | Crohn's disease Inflammatory bowel disease Monoclonal antibodies Ulcerative colitis |
النوع | Article Review |
الملفات في هذه التسجيلة
هذه التسجيلة تظهر في المجموعات التالية
-
الصحة العامة [467 items ]